Entospletinib has been shown to produce complete remission rates of 83–90% in a phase Ib/II trial (NCT02343939) when administered in combination with chemotherapy to patients with AML bearing a HOXA9/MEIS1 signature (including those with FLT3-ITDs, NPM1 mutations or MLL1-r) [143,144], suggesting that for AML patients with increased HOXA9 and MEIS1 expression, SYK inhibition might represent a potentially valuable therapy. Here, FLT3 is linked to acute myeloid leukemia.